^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | BL-M07D1 (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Excerpt:
...Inoperable locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors that have been histopathologically and/or cytologically confirmed and have failed standard therapy, or are...
Trial ID:
Source:
Title:
BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
Published date:
12/02/2023
Excerpt:
BL-M07D1 demonstrated encouraging efficacy in heavily pretreated HER2 expressing cancers, especially in HER2+ BC.
Trial ID:
Source:
Title:
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Published date:
10/16/2023
Excerpt:
ORR, % (95% CI)...42.3 (23-63.1)...43.5 (23.2-65.5)...60 (32.3-83.7)...BL-M07D1 demonstrated encouraging efficacy in heavily pretreated HER2 expressing cancers, especially in HER2-positive BC. The safety profile showed adequate safety and tolerability.
Trial ID:
